Xenon Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Net Income	-188.6	-182.39	-124.94	-77.09	-28.01	-40.03	Upgrade
Depreciation & Amortization	3.79	3.54	1.62	0.91	0.64	0.43	Upgrade
Share-Based Compensation	35.78	32.37	20.38	10.02	5.68	2.92	Upgrade
Other Operating Activities	-5.06	1.15	4.94	-1.54	-25.61	33.53	Upgrade
Operating Cash Flow	-154.09	-145.33	-98.43	-69.5	-48.12	-4.71	Upgrade
Capital Expenditures	-3.6	-5.62	-2.89	-2.05	-2.64	-1.24	Upgrade
Change in Investments	-206.4	-111.55	-293.11	-244.72	-14.19	-64.97	Upgrade
Investing Cash Flow	-209.99	-117.17	-296	-246.77	-16.82	-66.21	Upgrade
Share Issuance / Repurchase	353.52	353.52	278.47	447.54	102.54	27.52	Upgrade
Debt Issued / Paid	0	0	0	0	-16.74	0	Upgrade
Financing Cash Flow	353.52	353.52	278.47	447.54	85.8	27.52	Upgrade
Exchange Rate Effect	-0.05	0.38	-2.48	-0.59	-0.59	0.41	Upgrade
Net Cash Flow	-10.62	91.4	-118.45	130.68	20.25	-43	Upgrade
Free Cash Flow	-157.69	-150.94	-101.32	-71.55	-50.76	-5.95	Upgrade
Free Cash Flow Margin	-	-	-1074.03%	-388.09%	-157.81%	-87.19%	Upgrade
Free Cash Flow Per Share	-2.03	-2.26	-1.67	-1.64	-1.47	-0.23	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).